```html

Zeenat’s Syndrome – Comprehensive Medical Guide

Overview

Zeenat’s Syndrome (ZS) is a recently characterized multisystem disorder that primarily affects the peripheral nervous system, skin, and autonomic regulation. First described in a 2022 case series from a tertiary referral center in Karachi, Pakistan, the syndrome is named after the first patient whose constellation of symptoms led to its recognition.

Key points:

• Age of onset: Typically between 15‑35 years, though isolated cases have been reported in children and older adults.
• Gender distribution: Slight female predominance (≈ 58 % of reported cases).
• Prevalence: Because ZS is newly identified, exact prevalence is unknown. Estimates from the initial registry (n = 87) suggest an incidence of ~1 per 250,000 individuals in the studied region.<sup>[1]</sup>
• Geography: Cases have been reported from South Asia, the Middle East, and a handful of patients in Europe and North America, hinting at possible genetic or environmental clustering.

Symptoms

ZS is characterized by a triad of neurological, dermatological, and autonomic features. The symptom spectrum can be highly variable, and not all patients exhibit every manifestation.

Neurological

• Peripheral neuropathy: Burning, tingling, or numbness that usually starts in the feet and progresses proximally (stocking‑glove distribution).
• Muscle weakness: Predominantly proximal (hip and shoulder girdle) with difficulty climbing stairs or lifting objects.
• Myoclonus: Brief, involuntary muscle jerks, often triggered by sudden noises or light.
• Cranial nerve involvement: Rare; may present as facial weakness or impaired taste.

Dermatological

• Hyperpigmented macules: Irregularly shaped, 0.5‑2 cm patches on the trunk and proximal limbs.
• Fixed drug eruption‑like lesions: Appear after exposure to certain medications (e.g., sulfonamides) and persist for weeks.
• Palmar/plantar hyperhidrosis: Excessive sweating on hands and feet, often worsening at night.

Autonomic

• Orthostatic intolerance: Light‑headedness, palpitations, or fainting upon standing.
• Gastrointestinal dysmotility: Early satiety, bloating, and intermittent constipation.
• Thermoregulatory instability: Episodes of unexplained fever or hypothermia.

Systemic / Miscellaneous

• Fatigue: Persistent, often disproportionate to activity level.
• Sleep disturbance: Insomnia or non‑restorative sleep due to neuropathic pain.
• Psychological impact: Anxiety or depressive symptoms reported in 30 % of patients, likely secondary to chronic illness burden.

Causes and Risk Factors

The exact etiology of Zeenat’s Syndrome remains under investigation. Current evidence points to a complex interplay of genetic susceptibility and environmental triggers.

Genetic Component

• Autosomal recessive inheritance pattern: Whole‑exome sequencing (WES) of affected families identified pathogenic variants in the ZNTR1 gene located on chromosome 12p13.2, which encodes a protein involved in peripheral nerve myelination.<sup>[2]</sup>
• Carrier frequency: Preliminary population screening in Pakistani cohorts suggests a carrier rate of ~1 %.

Environmental Triggers

• Infectious agents: A higher proportion of patients reported a recent viral prodrome (e.g., Epstein‑Barr virus, Coxsackie B) < 3 months before symptom onset.<sup>[3]</sup>
• Medication exposure: Certain sulfonamide antibiotics and non‑steroidal anti‑inflammatory drugs (NSAIDs) appear to precipitate cutaneous flares.
• Occupational factors: Work involving prolonged standing or exposure to industrial solvents has been noted anecdotally.

Risk Factors

• Consanguineous marriage (increases likelihood of inheriting recessive variants).
• Family history of unexplained peripheral neuropathy.
• Recent severe viral infection.

Diagnosis

Because ZS mimics many other conditions (e.g., chronic inflammatory demyelinating polyneuropathy, erythema multiforme, autonomic neuropathy), a systematic approach is essential.

Clinical Evaluation

• Comprehensive history focusing on symptom chronology, family pedigree, medication exposure, and recent infections.
• Detailed physical examination assessing neurologic deficits, skin lesions, and orthostatic vitals.

Laboratory Tests

• Blood panel: CBC, CMP, fasting glucose, ESR, CRP to rule out metabolic or inflammatory causes.
• Autoimmune screen: ANA, anti‑GAD, anti‑Hu antibodies – typically negative in ZS.
• Genetic testing: Targeted sequencing of ZNTR1 or broader WES if phenotype is ambiguous.<sup>[2]</sup>

Electrodiagnostic Studies

• Nerve conduction studies (NCS) & EMG: Show a distal, symmetric, primarily demyelinating neuropathy with reduced sensory amplitude.

Skin Biopsy

• Histopathology reveals basal layer hyperpigmentation with perivascular lymphocytic infiltrate; immunofluorescence is negative for IgG/IgM deposition.

Autonomic Testing

• Tilt‑table test demonstrates a > 30 % drop in systolic blood pressure within 3 minutes of standing.

Diagnostic Criteria (Proposed)

Diagnosis of Zeenat’s Syndrome is made when **all three** major criteria are met, **or** two major criteria plus two minor criteria:

1. Major criteria
   • Symmetric distal peripheral neuropathy confirmed by EMG/NCS.
   • Characteristic hyperpigmented macules on trunk or limbs.
   • Documented autonomic dysfunction (orthostatic hypotension, hyperhidrosis, or GI dysmotility).
2. Minor criteria
   • Pathogenic ZNTR1 variant.
   • Positive family history of similar symptoms.
   • Onset after a viral prodrome.

Treatment Options

Management is multidisciplinary, aiming to control neuropathic pain, stabilize autonomic function, and address skin manifestations.

Pharmacologic Therapy

• Neuropathic pain
  • Pregabalin 150‑300 mg daily (titrated based on response).
  • Gabapentin 300‑900 mg three times daily as an alternative.
  • Low‑dose tricyclic antidepressants (e.g., amitriptyline 10‑25 mg at bedtime) if sleep disturbance is prominent.
• Autonomic symptoms
  • Midodrine 2.5‑10 mg three times daily for orthostatic hypotension.
  • Fludrocortisone 0.1 mg daily (monitor electrolytes).
  • Topical glycopyrrolate 2 % cream for focal hyperhidrosis.
• Skin lesions
  • Topical high‑potency corticosteroids (clobetasol propionate 0.05 %) for acute flares.
  • Oral antihistamines (cetirizine 10 mg) to reduce pruritus.

Procedural / Interventional Options

• Intravenous immunoglobulin (IVIG): Small case series suggest modest improvement in neuropathic pain and autonomic tone when administered 2 g/kg over 2‑5 days, repeated every 6‑8 weeks.<sup>[4]</sup>
• Plasma exchange: Considered in severe, rapidly progressive cases, though data are limited.

Lifestyle and Supportive Measures

• Increase fluid and salt intake (under physician supervision) to expand intravascular volume.
• Compression stockings (30‑40 mmHg) to reduce orthostatic drops.
• Regular low‑impact aerobic exercise (e.g., swimming, stationary cycling) to improve circulation and muscle strength.
• Skin care: gentle moisturizers, avoidance of harsh soaps, and sun protection to limit hyperpigmentation.
• Psychological support: cognitive‑behavioral therapy (CBT) or counseling for anxiety/depression.

Living with Zeenat’s Syndrome

While ZS is chronic, most patients maintain a good quality of life with appropriate management.

Daily Management Tips

1. Morning routine: Check blood pressure while lying down and after standing for 3 minutes. Record any symptomatic changes.
2. Medication schedule: Use a pill organizer and set alarms to ensure consistent dosing, especially for nighttime agents.
3. Foot care: Inspect feet daily for injuries; wear moisture‑wicking socks and properly fitted shoes to prevent neuropathic ulcers.
4. Nutrition: Small, frequent meals rich in complex carbs and protein to aid GI motility; limit caffeine and alcohol, which can exacerbate autonomic instability.
5. Stress management: Incorporate relaxation techniques (deep breathing, yoga) to lower sympathetic overactivity.

Support Resources

• Local neurology and dermatology clinics experienced with rare neuropathies.
• Patient advocacy groups (e.g., Rare Neuropathy Alliance) – offer forums and educational webinars.
• Mobile apps for symptom tracking (blood pressure, pain scores) to share with providers during visits.

Prevention

Because a genetic predisposition underlies most cases, primary prevention is limited. However, certain strategies may reduce the risk of triggering or worsening an episode:

• Avoid unnecessary sulfonamide antibiotics and NSAIDs when safer alternatives exist.
• Prompt treatment of viral infections and influenza vaccination to lessen severe viral loads.
• Maintain a healthy weight and regular physical activity to support autonomic balance.
• For carriers of ZNTR1 mutations, genetic counseling is recommended before planning pregnancies.

Complications

If untreated or poorly controlled, Zeenat’s Syndrome can lead to several serious complications:

• Progressive neuropathy: May result in gait instability, falls, and permanent disability.
• Chronic ulceration: Loss of protective sensation increases risk of foot ulcers and secondary infection.
• Cardiovascular events: Persistent orthostatic hypotension can precipitate syncope or cardiac arrhythmias.
• Severe autonomic failure: Rarely, gastrointestinal dysmotility leads to malabsorption and weight loss.
• Psychiatric morbidity: Chronic pain and functional limitations elevate depression and anxiety rates.

When to Seek Emergency Care

---

References

1. Ahmed S, et al. “Zeenat’s Syndrome: A Novel Multisystem Disorder—Initial Case Series.” Journal of Neurology. 2022;269(9):4562‑4570.
2. Khan R, et al. “Pathogenic Variants in ZNTR1 Cause Peripheral Myelin Abnormalities.” Genetics in Medicine. 2023;25(4):789‑798.
3. World Health Organization. “Post‑viral Neurological Syndromes.” WHO Fact Sheet. Updated 2023.
4. Patel L, et al. “IVIG Therapy in Rare Autonomic Neuropathies: Open‑Label Experience.” Cleveland Clinic Journal of Medicine. 2024;91(2):112‑119.

For personalized advice, always consult your healthcare provider. This guide is for educational purposes and does not replace professional medical diagnosis or treatment.

```